TY - JOUR T1 - Performance characteristics of the VIDAS<sup>®</sup> SARS-COV-2 IgM and IgG serological assays JF - medRxiv DO - 10.1101/2020.09.28.20196030 SP - 2020.09.28.20196030 AU - Nathalie Renard AU - Soizic Daniel AU - Nadège Cayet AU - Matthieu Pecquet AU - Frédérique Raymond AU - Sylvie Pons AU - Julien Lupo AU - Carole Tourneur AU - Catherine Pretis AU - Guillaume Gerez AU - Patrick Blasco AU - Maxime Combe AU - Imen Canova AU - Mylène Lesénéchal AU - Franck Berthier Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/24/2020.09.28.20196030.abstract N2 - The COVID-19 pandemic, caused by the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to spread worldwide. Serological testing for SARS-CoV-2-specific antibodies plays an important role in understanding and controlling the pandemics, notably through epidemiological surveillance. Well validated and highly specific SARS-CoV-2 serological assays are urgently needed. We describe here the analytical and clinical performance of VIDAS® SARS-CoV-2 IgM and VIDAS® SARS-CoV-2 IgG, two CE-marked, EUA-authorized, automated, qualitative assays for the detection of SARS-CoV-2-specific IgM and IgG, respectively. Both assays showed high within-run and within-laboratory precision (coefficients of variation &lt; 11.0%) and very low cross-reactivity towards sera of patients with a past common coronavirus or respiratory virus infection. Clinical specificity determined on up to 989 pre-pandemic healthy donors was ≥ 99% with a narrow 95% confidence interval for both IgM and IgG assays. Clinical sensitivity was determined on up to 232 samples from 130 RT-PCR-confirmed SARS-CoV-2 patients. The positive percent agreement (PPA) with SARS-CoV-2 PCR reached 100% at ≥ 16 days (VIDAS® SARS-CoV-2 IgM) and ≥ 32 days (VIDAS® SARS-CoV-2 IgG) of symptom onset. Combined IgM/IgG test results improved the PPA compared to each test alone. SARS-CoV-2 IgG seroconversion followed closely that of SARS-CoV-2 IgM and remained stable over time, while SARS-CoV-2 IgM levels rapidly declined. Interestingly, SARS-CoV-2-specific IgM and IgG responses were significantly higher in COVID-19 hospitalized vs. non-hospitalized patients. Altogether, the VIDAS® SARS-CoV-2 IgM and IgG assays are highly specific and sensitive serological tests suitable for the reliable detection of past acute SARS-CoV-2 infections.Competing Interest StatementJulien Lupo declares received research funding from bioMerieux for this study. Matthieu Pecquet declares a consulting contract with bioMerieux. Nathalie Renard, Soizic Daniel, Nadege Cayet, Frederique Raymond, Sylvie Pons, Carole Tourneur, Catherine Pretis, Guillaume Gerez, Patrick Blasco, Maxime Combe, Imen Canova, Mylene Lesenechal and Franck Berthier are employees from bioMerieux, an in vitro diagnostic company. Clinical TrialNCT04341142Funding StatementThis study was funded by bioMerieux (Marcy L Etoile, France) in accordance with Good Publication Practice (GPP3) guidelines (http://www.ismpp.org/gpp3).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics RCB ID 2020-A00932-37 (Review Committee Board) was approved by the French national review board for biomedical research in April 2020 (Comite de Protection des Personnes Sud Mediterranee I, Marseille, France).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available upon request to bioMerieux. ER -